Skip to Content
Merck
CN
  • Function of inhibitory micronetworks is spared by Na+ channel-acting anticonvulsant drugs.

Function of inhibitory micronetworks is spared by Na+ channel-acting anticonvulsant drugs.

The Journal of neuroscience : the official journal of the Society for Neuroscience (2014-07-18)
Leonie Pothmann, Christina Müller, Robert G Averkin, Elisa Bellistri, Carolin Miklitz, Mischa Uebachs, Stefan Remy, Liset Menendez de la Prida, Heinz Beck
ABSTRACT

The mechanisms of action of many CNS drugs have been studied extensively on the level of their target proteins, but the effects of these compounds on the level of complex CNS networks that are composed of different types of excitatory and inhibitory neurons are not well understood. Many currently used anticonvulsant drugs are known to exert potent use-dependent blocking effects on voltage-gated Na(+) channels, which are thought to underlie the inhibition of pathological high-frequency firing. However, some GABAergic inhibitory neurons are capable of firing at very high rates, suggesting that these anticonvulsants should cause impaired GABAergic inhibition. We have, therefore, studied the effects of anticonvulsant drugs acting via use-dependent block of voltage-gated Na(+) channels on GABAergic inhibitory micronetworks in the rodent hippocampus. We find that firing of pyramidal neurons is reliably inhibited in a use-dependent manner by the prototypical Na(+) channel blocker carbamazepine. In contrast, a combination of intrinsic and synaptic properties renders synaptically driven firing of interneurons essentially insensitive to this anticonvulsant. In addition, a combination of voltage imaging and electrophysiological experiments reveal that GABAergic feedforward and feedback inhibition is unaffected by carbamazepine and additional commonly used Na(+) channel-acting anticonvulsants, both in control and epileptic animals. Moreover, inhibition in control and epileptic rats recruited by in vivo activity patterns was similarly unaffected. These results suggest that sparing of inhibition is an important principle underlying the powerful reduction of CNS excitability exerted by anticonvulsant drugs.

MATERIALS
Product Number
Brand
Product Description

USP
Carbamazepine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Carbamazepine, meets USP testing specifications
Supelco
Carbamazepine, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Carbamazepine, analytical standard
Carbamazepine, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
5,5-Diphenylhydantoin, ≥98%
Sigma-Aldrich
Pilocarpine nitrate, meets USP testing specifications
Supelco
Phenytoin, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Phenytoin, United States Pharmacopeia (USP) Reference Standard
Supelco
Carbamazepine solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®
Sigma-Aldrich
Hydrobromic acid, 48 wt. % in H2O, ≥99.99%
Sigma-Aldrich
Hydrobromic acid, ACS reagent, 48%
Phenytoin for system suitability, European Pharmacopoeia (EP) Reference Standard
Phenytoin, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Hydrobromic acid, reagent grade, 48%